The Indian Pharmaceutical Market (IPM) has registered a strong growth of 10.8 per cent during May 2018 to Rs.10,583 crore. The IPM clocked double digit growth for the first time in last 12 months. The volumes have posted a positive growth, however price component is dragging the market. According to AIOCD Awacs monthly report, during the May quarter, the market saw a better volume growth at 7.8 per cent and price growth of one per cent. The new products fared comparatively better at growth of 2.7 per cent. The FDC related market showed growth of 18.5 per cent while the non FDC market showed a growth of 10.6 per cent. The single molecules grew at 10.8 per cent for the month.

Among the leading 10 corporates, Lupin clocked highest growth of 17.5 per cent followed by Abbott at 15.9 per cent and Torrent at 14.2 per cent. Among the top 50 companies, 49 companies achieved positive growth of IPM during May 2018. Amongst the top 50 companies, AstraZeneca has the highest growth of 40.2 per cent followed by Boehringer Ingelheim growing at 21.6 per cent followed by Glenmark and Systopic at 20 per cent. Sun portfolio has show a growth of 12 per cent while, Ranbaxy has slowed down at 2 per cent. Emcure clocked growth of 11.9 per cent and Zuventus 15.1 per cent. Total 16 companies launched in last 36 months.

Indian companies achieved sales of Rs.8,407 crore with growth of 10.5 per cent while the MNC have grown faster at 11.9 per cent to Rs.2,176 crore. Amongst the top 60 MNCs, AstraZeneca was the fastest growing at 40.2 per cent, followed by Boehringer Ingelheim and Danone. In the non-NLEM category Indian companies showed a growth of 11 per cent whereas MNCs grew at 12.8 per cent. The NLEM 2013 containing molecules market showed growth at 7.1 per cent whereas the non NLEM market grew at 11.4 per cent resulting in an overall growth of 8.9 per cent during May 2018.

From therapy perspective, 19 therapies are showing a positive growth. Respiratory market posted a double growth of 15.4 per cent, gastrointestinal showed an improved growth at 11.3 per cent and pain and analgesic market showed a growth of 9.8 per cent. Anti-diabetic market has posted a double digit growth of 14.1 per cent and cardiac is at double digit growth of 13 per cent, Neuro/CNS also showed a double growth of 11.2 per cent. Anti infectives posted a positive growth 6 per cent while VMS market achieved growth of 9.9 per cent.

From the regional perspective, 30 regions have posted positive growth for month of May 2018. North Gujarat market grew the highest at 24.1 per cent followed by UP East growth at 23.2 per cent and MP at 18.72 per cent.

Amoxycillin plus clavulanic acid market achieved recovery at 4.9 per cent to Rs.132.6 crore and glimepiride plus metformin market registered growth of 7 per cent to Rs.184.9 crore. Azilsartan plan market is nnow valued at Rs.67.8 crore on MAT basis. Sofosbuvir and its combination market has reached at Rs.620.9 crore. The luliconazole market is worth Rs.299.4 crore, while tenegliptin and its combinations are almost at Rs.700 crore. The market for paracetamol plain is growing double digit rate at 12.1 per cent on monthly basis, plain atorvastatin has posted a growth of 4.2 per cent.

Among the major brands, Mixtard has posted monthly sales worth Rs.46 crore, while Spasmoproxivon plus has registered sales of Rs.35 crore. Glycomet GP is at Rs.38 crore, Lantus is at Rs.34 crore and Galvus Met at Rs.35 crore and Liv 52 at Rs.32 crore. Janumet reached at Rs.38 crore and Augmentin at Rs.26 crore during May 2018. Among the recent new molecule launches, Azilsartand combinations are now valued at Rs.71 crore. Total 51 new brands launched and on MAT basis with Zilarbi (Emcure) leading followed by Aztric (Intas) and Abel (Lupin). Luliconazole segment is worth almost Rs.300 crore and there are already 59 new brands launched in the segment. Within the VMS category there have been 24 brands launched for the month of May 2018 and that in cardiac there have been 11 brands.